Access Bio (XKRX:950130) EV-to-EBIT : 1.16 (As of May. 27, 2024)

Access Bio EV-to-EBIT Chart

Access Bio Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT		Get a 7-Day Free Trial					-5.19	12.20	1.70	-	-14.96

Access Bio Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-1.28	-12.83	4.16	-14.96	0.76

Competitive Comparison of Access Bio's EV-to-EBIT

For the Diagnostics & Research subindustry, Access Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Access Bio's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Access Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Access Bio's EV-to-EBIT falls into.

Access Bio EV-to-EBIT Calculation

Access Bio's EV-to-EBIT for today is calculated as:

Access Bio's current Enterprise Value is ₩-64,429 Mil.
Access Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-55,445 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Access Bio  (XKRX:950130) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Access Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Access Bio's Enterprise Value for the quarter that ended in Mar. 2024 was ₩-41,944 Mil.
Access Bio's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-55,445 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Access Bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Access Bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Access Bio (XKRX:950130) Business Description